Hodge R H
Semin Arthritis Rheum. 1985 Feb;14(3 Suppl 1):3-6. doi: 10.1016/0049-0172(85)90052-6.
Since the initial marketing in the early 1970s of the nonsteroidal anti-inflammatory agents of the propionic acid type, there has been a gradual escalation of the dosage recommendation for each of these drugs. In contrast, the dosage recommendation for piroxicam has remained constant. In this 12-week, double-blind crossover study, the standard dose of piroxicam 20 mg/d has been compared with the newly recommended dosage of naproxen 500 mg twice a day in 19 patients with active osteoarthritis. In the piroxicam treatment interval, there was statistically significant improvement in six of nine clinical parameters as compared with five of nine clinical parameters for the naproxen treatment interval. Adverse experiences with both drugs were mild to moderate. Both piroxicam and naproxen resulted in statistically significant improvement in right grip strength, the time to walk 50 feet, daily activity assessment, and in the total joint pain. In addition, piroxicam resulted in statistically significant improvement in both the physician and patient assessment of disease activity. Naproxen treatment was associated with a statistically significant decrease in total joint swelling.
自20世纪70年代初丙酸类非甾体抗炎药首次上市以来，这些药物中每种药物的推荐剂量都在逐渐增加。相比之下，吡罗昔康的推荐剂量一直保持不变。在这项为期12周的双盲交叉研究中，将19例活动性骨关节炎患者中吡罗昔康的标准剂量20mg/天与新推荐的萘普生剂量500mg每日两次进行了比较。在吡罗昔康治疗期间，与萘普生治疗期间九个临床参数中的五个相比，九个临床参数中的六个有统计学意义的改善。两种药物的不良经历均为轻度至中度。吡罗昔康和萘普生均使右手握力、行走50英尺的时间、日常活动评估以及总关节疼痛有统计学意义的改善。此外，吡罗昔康在医生和患者对疾病活动的评估中均有统计学意义的改善。萘普生治疗与总关节肿胀的统计学显著降低相关。
